Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
Dyadic International (NASDAQ: DYAI) has received a $4.5 million funding award from CEPI to accelerate protein-based vaccine development using their C1 filamentous fungus technology. The funding will be directed to Fondazione Biotecnopolo di Siena (FBS) for proof-of-concept research.
The project aims to demonstrate that C1 technology could reduce vaccine production time from the current 4-6 months to just 35 days, significantly accelerating Phase 1 trials. Unlike traditional mammalian cell production, C1 fungus can rapidly produce quality vaccine proteins without extensive testing requirements.
The research will compare SARS-CoV-2 spike protein production using both C1 fungus and mammalian cell approaches. If successful, the technology could enable faster, more cost-effective vaccine manufacturing, particularly beneficial for regions with less established infrastructure, supporting the G7 and G20's 100 Days Mission for pandemic response.
Dyadic International (NASDAQ: DYAI) ha ricevuto un da CEPI per accelerare lo sviluppo di vaccini a base di proteine utilizzando la loro tecnologia di fungo filamentoso C1. Il finanziamento sarà destinato alla Fondazione Biotecnopolo di Siena (FBS) per la ricerca di prova di concetto.
Il progetto mira a dimostrare che la tecnologia C1 potrebbe ridurre il tempo di produzione dei vaccini dagli attuali 4-6 mesi a soli 35 giorni, accelerando significativamente le sperimentazioni di Fase 1. A differenza della produzione tradizionale con cellule di mammifero, il fungo C1 può produrre rapidamente proteine vaccinali di qualità senza requisiti di test estesi.
La ricerca confronterà la produzione della proteina spike del SARS-CoV-2 utilizzando sia l'approccio del fungo C1 che quello delle cellule di mammifero. Se avrà successo, la tecnologia potrebbe consentire una produzione di vaccini più rapida ed economica, particolarmente vantaggiosa per le regioni con infrastrutture meno consolidate, sostenendo la Missione dei 100 Giorni del G7 e del G20 per la risposta alle pandemie.
Dyadic International (NASDAQ: DYAI) ha recibido un financiamiento de 4,5 millones de dólares de CEPI para acelerar el desarrollo de vacunas basadas en proteínas utilizando su tecnología de hongo filamentoso C1. El financiamiento se destinará a la Fundación Biotecnopolo de Siena (FBS) para la investigación de prueba de concepto.
El proyecto tiene como objetivo demostrar que la tecnología C1 podría reducir el tiempo de producción de vacunas de los actuales 4-6 meses a solo 35 días, acelerando significativamente los ensayos de Fase 1. A diferencia de la producción tradicional con células de mamíferos, el hongo C1 puede producir rápidamente proteínas de vacuna de calidad sin requisitos de pruebas extensas.
La investigación comparará la producción de la proteína espiga del SARS-CoV-2 utilizando tanto el enfoque del hongo C1 como el de células de mamíferos. Si tiene éxito, la tecnología podría permitir una fabricación de vacunas más rápida y rentable, siendo particularmente beneficiosa para las regiones con infraestructura menos establecida, apoyando la Misión de 100 Días del G7 y del G20 para la respuesta a pandemias.
다이애딕 인터내셔널 (NASDAQ: DYAI)은 CEPI로부터 450만 달러의 자금 지원을 받아 C1 필라멘트 곰팡이 기술을 사용하여 단백질 기반 백신 개발을 가속화합니다. 이 자금은 개념 증명 연구를 위해 시에나 생명공학 재단(FBS)으로 전달될 것입니다.
이 프로젝트는 C1 기술이 현재의 4-6개월에서 단 35일로 백신 생산 시간을 줄일 수 있음을 입증하는 것을 목표로 합니다. 전통적인 포유류 세포 생산과 달리 C1 곰팡이는 광범위한 테스트 요구 없이 품질 좋은 백신 단백질을 신속하게 생산할 수 있습니다.
이 연구는 C1 곰팡이와 포유류 세포 접근 방식을 사용하여 SARS-CoV-2 스파이크 단백질 생산을 비교할 것입니다. 성공할 경우, 이 기술은 더 빠르고 비용 효율적인 백신 제조를 가능하게 할 수 있으며, 특히 인프라가 덜 발달한 지역에 유리하며, G7 및 G20의 팬데믹 대응을 위한 100일 미션을 지원합니다.
Dyadic International (NASDAQ: DYAI) a reçu une subvention de 4,5 millions de dollars de CEPI pour accélérer le développement de vaccins à base de protéines en utilisant leur technologie de champignon filamenté C1. Le financement sera dirigé vers la Fondazione Biotecnopolo di Siena (FBS) pour des recherches de preuve de concept.
Le projet vise à démontrer que la technologie C1 pourrait réduire le temps de production des vaccins des 4-6 mois actuels à seulement 35 jours, accélérant ainsi significativement les essais de Phase 1. Contrairement à la production traditionnelle avec des cellules de mammifères, le champignon C1 peut produire rapidement des protéines vaccinales de qualité sans exigences de tests étendues.
La recherche comparera la production de la protéine spike du SARS-CoV-2 en utilisant à la fois l'approche du champignon C1 et celle des cellules de mammifères. Si cela réussit, la technologie pourrait permettre une fabrication de vaccins plus rapide et plus rentable, ce qui serait particulièrement bénéfique pour les régions avec une infrastructure moins développée, soutenant la Mission des 100 Jours du G7 et du G20 pour la réponse aux pandémies.
Dyadic International (NASDAQ: DYAI) hat eine Förderung in Höhe von 4,5 Millionen Dollar von CEPI erhalten, um die Entwicklung von proteinbasierten Impfstoffen mit ihrer C1 filamentösen Pilztechnologie zu beschleunigen. Die Finanzierung wird an die Fondazione Biotecnopolo di Siena (FBS) für Forschungsprojekte zur Machbarkeitsprüfung geleitet.
Das Projekt zielt darauf ab, zu demonstrieren, dass die C1-Technologie die Produktionszeit für Impfstoffe von derzeit 4-6 Monaten auf nur 35 Tage verkürzen könnte, was die Phase-1-Studien erheblich beschleunigt. Im Gegensatz zur traditionellen Produktion mit Säugetierzellen kann der C1-Pilz schnell qualitativ hochwertige Impfstoffproteine ohne umfangreiche Testanforderungen produzieren.
Die Forschung wird die Produktion des SARS-CoV-2-Spike-Proteins mithilfe sowohl des C1-Pilzes als auch von Säugetierzellen vergleichen. Wenn dies erfolgreich ist, könnte die Technologie eine schnellere und kostengünstigere Impfstoffherstellung ermöglichen, was insbesondere für Regionen mit weniger entwickelter Infrastruktur von Vorteil wäre und die 100-Tage-Mission von G7 und G20 zur Pandemiebewältigung unterstützen würde.
- Secured $4.5M CEPI funding for C1 technology development
- Technology could reduce vaccine production time from 4-6 months to 35 days
- Potential for more cost-effective manufacturing process
- Technology enables easier scaling with reduced infrastructure requirements
- Technology still in proof-of-concept phase, success not guaranteed
- Requires comparative studies to prove effectiveness against traditional methods
Insights
Dyadic's $4.5 million CEPI funding award represents strategic validation for the company's C1 technology platform. While the funding flows to Fondazione Biotecnopolo di Siena (FBS) rather than directly to Dyadic, the research specifically centers on Dyadic's proprietary C1 filamentous fungus technology, creating significant partnership value beyond the immediate financial impact.
This validation comes from a globally respected organization deeply connected to pandemic preparedness initiatives embraced by G7 and G20 leaders. For a company with a modest
The investment thesis centers on C1's potential to compress vaccine development timelines from 4-6 months to just 35 days while reducing production costs through simpler manufacturing requirements. If successful, this positions Dyadic's platform as a potential cornerstone technology for regional vaccine manufacturing infrastructure, particularly in areas with less established biopharmaceutical capabilities.
The research will initially focus on comparing SARS-CoV-2 spike proteins produced via C1 versus traditional mammalian cells, providing a clear benchmark for efficacy. Success would create a pathway to testing with additional pathogens of interest to CEPI, potentially expanding application scope.
While commercial impact remains distant as this represents research-stage development, the third-party validation substantiates Dyadic's technology claims and creates a foundation for potential future partnerships, licensing agreements, and expanded applications in both human and animal health sectors.
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vaccines.
CEPI is providing US
While producing protein antigens in mammalian cells is an effective way of developing protein-based vaccines, the process can take four to six months. This is because they require the creation of a stable cell line—cells engineered to consistently produce the target vaccine protein—which involves extensive testing. In contrast, a C1 fungus cell line could be used to rapidly produce a pool of cells that generate the same quality vaccine protein without the need for such time-consuming testing, enabling faster protein production. This project could slash the development time for vaccine production and release to just 35 days, helping vaccines to enter Phase 1 trials much sooner.
The researchers also hope that the C1 fungus technology will produce large quantities of proteins which can be easily scaled, with a reduced need for complex or expensive biopharmaceutical facilities compared to those required for mammalian cell cultures. This affordability means the technology would be suitable for transfer to regional manufacturing, where vaccine manufacturing infrastructure may be less established, helping to meet local needs in support of greater access.
The CEPI-FBS partnership supports the 100 Days Mission—a goal embraced by leaders of the G7 and G20 to reduce vaccine development timelines to a little over three months in response to a pandemic threat.
Dr Raafat Fahim, Interim Executive Director of Manufacturing and Supply Chain, CEPI, said, “Protein-based vaccines play a crucial role in combating emerging infectious diseases. However, the current manufacturing processes for producing these vaccines can be both costly and time-consuming. By leveraging the growth capabilities of fungi, we can potentially produce the necessary proteins up to four to six times faster than traditional methods. This would accelerate the transition of promising vaccine candidates into clinical trials and enable faster large-scale production during emergencies. The flexibility, speed, and affordability of this fungal-based approach make it especially valuable in outbreak situations where time is of the essence.”
Prof. Rino Rappuoli , Scientific Director FBS, said, “There is a huge need for new technology platforms that can deliver vaccines that can be produced rapidly, that can be affordable for every person of the planet, that can easily be stored in refrigerators, and that can be rapidly scaled to billions of doses. The collaboration with CEPI allows the Fondazione Biotecnopolo di Siena to work on a technology that has the potential to deliver this type of vaccine. It is a great honour to be able to be part of a global network dedicated to the preparedness against future epidemics and pandemics. We will face many important health challenges, and thanks to this innovative technology, we will put all our effort into finding solutions to overcome them, including in low- and middle-income countries.”
Mark Emalfarb, Dyadic’s CEO, said, “We are grateful for CEPI’s funding and the support of Fondazione Biotecnopolo di Siena, led by Dr. Rino Rappuoli, in advancing Dyadic’s C1 platform for faster, more affordable vaccines and treatments. This funding accelerates C1’s development for pandemic preparedness through a One Health approach, reducing costs, increasing productivity, and improving global vaccine access. With CEPI’s support, we aim to prevent zoonotic outbreaks and strengthen global health security. But to fully realise these benefits, policymakers must act now, as CEPI urges, before the next pandemic strikes—proactive investment is critical to safeguarding human and animal health.”
Specifically, CEPI’s funding will seek to produce a SARS-CoV-2 spike protein—an antigen that trains the immune system to recognise and fight off the virus—using both the innovative C1 fungus and the more traditional mammalian cell approach. Researchers will then compare the two to see if the antigen produced by the C1 fungus is comparable in structure and immunogenicity to those produced in mammalian cells.
If successful, the next phase of the project will focus on selecting an antigen from a pathogen of interest to CEPI. This will be used for development and to demonstrate a reduced timeline for vaccine development.
To see the original press release issued by CEPI, please visit CEPI’s website at https://cepi.net/exploiting-fungus-growth-rapid-and-affordable-vaccine-development.
About Dyadic International, Inc.
Dyadic International, Inc. is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, as well as other biologic vaccines, antibodies, and other biological products.
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit http://www.dyadic.com.
About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.
About FBS
Fondazione Biotecnopolo di Siena (FBS) is a nonprofit, private legal entity with registered office and operational headquarters in Siena. The founding members include the Ministry of Universities and Research, the Ministry of Health, the Ministry of Economy and Finance and the Ministry of Enterprise and Made in Italy. FBS is a strategic national project that aims to develop applied research and innovation in the field of biotechnologies and life sciences. The FBS mission is focused on the research, development and production of vaccines and monoclonal antibodies for the treatment of pandemics and emerging infectious diseases.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our research projects and third-party collaborations and of our efforts to use C1 to accelerate the development of protein-based vaccines. Forward-looking statements generally can be identified by use of the words “could,” “would,” “hope,” “aim,” “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” and other similar terms or variations of them or similar terminology. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) competition, including from alternative technologies; (iv) the results of nonclinical studies and clinical trials; (v) our capital needs; (vi) changes in global economic and financial conditions; (vii) our reliance on information technology; (viii) our dependence on third parties; (ix) government regulations and environmental, social and governance issues; and (x) intellectual property risks. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.
Contact:
Dyadic International, Inc.
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
FAQ
How much funding did Dyadic (DYAI) receive from CEPI for vaccine development?
What is the potential time reduction for vaccine production using Dyadic's C1 technology?
What specific protein will be tested first in Dyadic's CEPI-funded research?
How does Dyadic's C1 technology differ from traditional vaccine production methods?
